3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
3
CNS
2
Conditions
Brain Neoplasms
19
Breast Neoplasms
14
Glioblastoma
4
Squamous Cell Carcinoma of Head and Neck
3
Salivary Gland Neoplasms
3
Neoplasm Metastasis
3
Esthesioneuroblastoma, Olfactory
3
Stomach Neoplasms
2
Neoplasms
2
Meningeal Neoplasms
2
Meningeal Carcinomatosis
2
Head and Neck Neoplasms
2
Glioma
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms, Male
2
Bile Duct Neoplasms
2
Astrocytoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Liver Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Appendiceal Neoplasms
1
Interventions
Trastuzumab
2
Radiotherapy
2
Capecitabine
2
tucatinib
1
sapanisertib
1
pertuzumab
1
patritumab deruxtecan
1
paclitaxel-Angiopep-2 conjugate
1
omburtamab I-131
1
fludarabine
1
eribulin
1
avelumab
1
WP 744
1
Temozolomide
1
Spinal Puncture
1
Rituximab
1
Psychiatric Rehabilitation
1
Phlebotomy
1
Methotrexate
1
Cyclophosphamide
1
Amplified Fragment Length Polymorphism Analysis
1
AZD1390
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Meningeal Neoplasms
×
Capecitabine
×
CNS
×
Clear all
NCT05800275
2025-11-18
ETIC-LM
UNICANCER
Phase 2
Recruiting
30 enrolled
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled